MiVu™ Mucosal Integrity Testing System

 Primary diagnostic tools used in practice today for suspected GERD include endoscopy and ambulatory reflux monitoring. These commonly used tools have significant limitations, resulting in many tested patients having a vague, questionable diagnosis that is not an effective guide for therapy. Esophageal mucosal injury detected by endoscopic evaluation is present in less than 30% of patients.i Currently available pH technology only measures the acidity of refluxed material at a single point along the esophagus. Furthermore, these tests fail to account for day-to-day variability of reflux, as they only provide a 24- to 48-hour snapshot of a disease process that is chronic in nature.ii Thus, current diagnostic testing in GERD is suboptimal and can have false-negative rates of nearly 30% in patients that have endoscopic esophagitis.

Why MiVu?

Using esophageal mucosal integrity measurements, clinicians are able to easily differentiate certain esophageal disorders and monitor treatment response in GERD.

In those patients with nonerosive disease who had abnormal reflux by pH monitoring, MI values were similar to those with erosive esophagitis. MI was superior in predicting erosive reflux when compared to pH monitoring, with a specificity of 95% and positive predictive value of 96% compared to 64% and 40%, respectively.v Despite the lack of obvious mucosal changes at endoscopy, MI can differentiate those with abnormal reflux pattern from those with normal reflux parameters.

MI also accurately predicted EoE during endoscopy with a sensitivity of 100% and specificity of 96% without the need for Our findings support the possibility that in vivo measurement of esophageal mucosal impedance may be an accurate means of assessing activity in a patient with EoE without the need for obtaining esophageal biopsy specimens.

Mucosal Integrity Testing System

Instantly detect GERD, EoE, and Non-GERD and monitor treatment response in GERD and EoE with MiVu